Neuroendocrine tumor Tag

13 Jun

Posted at 14:54h in ASCO, Author Interviews, Cancer Research, Radiation Therapy
MedicalResearch.com Interview with: [caption id="attachment_42379" align="alignleft" width="150"]Jonathan Strosberg MD Moffitt Cancer Center Tampa, FL Dr. Strosberg[/caption] Jonathan Strosberg MD Moffitt Cancer Center, Tampa, FL MedicalResearch.com: What is the background for this study? Response: Neuroendocrine tumor (NET) progression is associated with deterioration in quality of life. We assessed the impact of 177Lu-Dotatate treatment on time to deterioration in health-related quality of life in patients with advanced midgut neuroendocrine tumors in the NETTER-1 study.